Meflynate Xl

Methylphenidate Hydrochloride, the active ingredient in Meflynate Xl, is a central nervous system stimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder and narcolepsy in children, adolescents, and adults.

GNH USA supplies Meflynate Xl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate Hydrochloride acts on central nervous system pathways that regulate attention and wakefulness.

- Attention deficit hyperactivity disorder (ADHD): improves focus, reduces hyperactivity and impulsivity in children, adolescents and adults. - Narcolepsy: decreases excessive daytime sleepiness and reduces the frequency of cataplexy episodes.

Meflynate Xl may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced desire for food, potentially leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: abdominal discomfort or nausea.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, arrhythmia, or chest pain. - Psychosis: new or worsening hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or difficulty breathing.

Before prescribing Meflynate Xl, clinicians should consider several safety measures.

- Cardiovascular assessment: evaluate blood pressure and heart rate prior to initiation. - Psychiatric history: screen for pre‑existing psychosis, bipolar disorder, or severe anxiety. - Substance use: avoid use in patients with a history of drug abuse. - Concomitant medications: review for drugs that may increase stimulant effects. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Meflynate Xl can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate hypertensive crisis. - Tricyclic antidepressants: may increase risk of cardiovascular side effects. - Antihypertensive agents: stimulant effect can counteract blood‑pressure‑lowering drugs.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors: can raise methylphenidate plasma concentrations. - Alcohol: may potentiate central nervous system stimulation and increase adverse effects.